License, Commercialization and Supply Agreements (Details 2) (USD $)	12 Months Ended		0 Months Ended	12 Months Ended	0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Oct. 10, 2013 License and commercialization agreement STENDRA Auxilium Pharmaceuticals, Inc.	Dec. 31, 2013 License and commercialization agreement STENDRA Auxilium Pharmaceuticals, Inc.	Oct. 10, 2013 License and commercialization agreement STENDRA Auxilium Pharmaceuticals, Inc. Maximum	Oct. 10, 2013 License and commercialization agreement Approval by the FDA STENDRA Auxilium Pharmaceuticals, Inc. Forecast	Dec. 11, 2013 License and commercialization agreement Milestone based on net sales target met Maximum	Oct. 10, 2013 License and commercialization agreement Milestone based on net sales target met STENDRA Auxilium Pharmaceuticals, Inc. Forecast
License, Commercialization and Supply Agreements
Termination period of the agreement from the launch of the product			10 years
Period from the STENDRA launch in the U.S after which the agreement can be terminated by the counterparty			1 year
Notice period for termination of the agreement by the counterparty after one year anniversary of the STENDRA launch in the U.S			180 days
Notice period for termination of the agreement by the counterparty upon the entry of a generic avanafil product into the market			30 days
Period available to the counterparty to cure the exclusion from participation in the U.S. federal healthcare programs in order to avoid the termination of the agreement by the entity					120 days
Upfront payments received			$ 30,000,000
Amount of regulatory milestone payment which the entity is eligible to receive						15,000,000	45,000,000	255,000,000
License revenue	55,838,000			30,400,000
Revenue recognized from initial product delivered	$ 25,244,000	$ 2,012,000		$ 1,100,000